In the context of the "Healthy China" initiative and the strategy of industrial transformation and upgrading, pharmaceutical innovation capability has emerged as an indispensable and crucial element for the development of the "Healthy China" strategy. This paper first comprehensively reviews theoretical perspectives on domestic and international pharmaceutical innovation capability research. Subsequently, it deeply analyzes the multiple factors influencing the pharmaceutical innovation capability in Dongguan. The study adopts the expert consultation method to establish evaluation criteria, utilizes the Analytic Hierarchy Process (AHP) to determine indicator weights and validate their rationality, and ultimately applies a fuzzy comprehensive evaluation model to process and analyze the data. The research results indicate that the constructed pharmaceutical innovation capability evaluation system exhibits significant advantages in terms of scientificity and practicality. The analysis of the comprehensive evaluation values reveals a positive development trend in Dongguan's pharmaceutical innovation capability, with the composite index continuously rising. However, it is still necessary to strengthen relevant policy support in order to promote the sustainable development of pharmaceutical innovation in Dongguan.

Yue Lu, Xusheng Zhang, Xiaoyan Cheng. Research on Evaluation of Dongguan Pharmaceutical Innovation Ability under the Background of Industrial Transformation and Upgrading Strategy. Academic Journal of Humanities & Social Sciences (2023) Vol. 6, Issue 20: 62-70. https://doi.org/10.25236/AJHSS.2023.062011.

[1] Bjerrum, O. J. (2011). Excellence in education and training advances competitiveness of the pharmaceutical industry in Europe. European Journal of Pharmaceutical Sciences, 44, 174-175.

[2] Mahajan, V. (2018). Structural changes and trade competitiveness in the Indian pharmaceutical industry in the product patent regime. International Journal of Pharmaceutical and Healthcare Marketing, 13.

[3] Nybakk, E., Crespell, P., Hansen, E., & Lunnan, A. (2009). Antecedents to forest owner innovativeness: An investigation of the non-timber forest products and services sector. Forest Ecology and Management, 257(2), 608-618.

[4] Rossi, F., & Cebula, R. (2015). Ownership Structure and R&D: An Empirical Analysis of Italian listed companies. Paolo Sylos Labini Quarterly Review, 68.

[5] Li, B. (2013). Construction and cluster analysis of the evaluation index system of China's pharmaceutical industry's technological innovation capability (in Chinese). Journal of Fujian University of Traditional Chinese Medicine, 04, 63-66.

[6] Wu, L. X., Shan, L. Q., Gao, S., & Wang, Y. F. (2019). Evaluation of technological innovation capability of China's pharmaceutical manufacturing industry based on principal component analysis (in Chinese). Science and Management, 04, 23-28.

[7] Cao, X., & Ruan, X. J. (2020). Research on evaluation of innovative development capability of China's pharmaceutical enterprises based on factor analysis method (in Chinese).China Pharmacy, 16, 1931-1937.

[8] Liu, P. W., Sui, N. N., & Liu, L. R. (2015). Research on the evaluation of innovation ability of pharmaceutical high-tech enterprises from the perspective of patent analysis (in Chinese). China Pharmaceuticals, 14, 7-9.

[9] Guo, X. Q., & Sun, Y. M. (2020). Evaluation method of innovation capability of high-tech enterprises based on priority hierarchical entropy. (in Chinese).Industrial Engineering, 05, 124-131+139.

[10] Zhang, M. M., & Mao, N. Y. (2020). Evaluation of innovation capability and potential of pharmaceutical innovation in China, the United States, and Japan based on dynamic TOPSIS method (in Chinese). Science and Technology Management Research, 21, 23-30.